Multiple Endocrine Neoplasia

What is multiple endocrine neoplasia?

Multiple endocrine neoplasia (MEN) is an inherited genetic multiple endocrine neoplasia that causes tumors to grow in several of the body’s hormone-producing, endocrine organs. MEN syndromes are traditionally divided into two forms: type 1 and type 2.

MEN type 1 (MEN1) typically involves tumors of the parathyroid glands, pituitary gland, and pancreas. MEN type 2 (MEN2) is more commonly associated with medullary thyroid cancer and pheochromocytomas. These tumors can be benign or malignant.

Meet Curtis

His family has a history of multiple endocrine neoplasia, a group of rare disorders that can make them more likely to develop tumors in the endocrine glands, including the thyroid.

black and white photo of curtis, who had a thyroidectomy, in a hospital bed

How we care for MEN

Children with MEN1 and MEN2 are treated at Dana-Farber/Boston Children's Cancer and Blood Disorders Center through our Endocrine-Oncology Program and the Boston Children’s Hospital Thyroid Program. Our integrated pediatric oncology service offers — in one specialized program — the combined expertise of a leading cancer center and a premier children’s hospital. We build a team to treat your child consisting of oncologists, endocrinologists, genetic counselors, and surgeons.

Our areas of research for MEN

Children who are treated through our Endocrine-Oncology Program benefit from the work of our basic and clinical researchers, who are striving to understand the scientific causes of endocrine cancers. Their work can result in the introduction of new treatment options. We are a world leader in translational research, bringing laboratory advances to the bedside and into doctors’ offices as quickly as possible.

Clinical Trials

Research studies evaluating new treatment approaches are a major offering at Dana-Farber/Boston Children’s. For many children with rare or hard-to-treat conditions, clinical trials provide new options.

In addition to launching our own clinical trials, we also offer trials available through collaborative groups such as the Children's Oncology Group (COG). If your child has a progressive or recurrent tumor, she may be eligible for a number of experimental therapies available through these groups or from one of our independent clinical investigators.